Anthony T Podany1, Yajing Bao2, Susan Swindells3, Richard E Chaisson4, Janet W Andersen2, Thando Mwelase5, Khuanchai Supparatpinyo6, Lerato Mohapi7, Amita Gupta8, Constance A Benson9, Peter Kim10, Courtney V Fletcher11. 1. College of Pharmacy, University of Nebraska Medical Center, Omaha. 2. Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts. 3. Infectious Diseases, Internal Medicine, University of Nebraska Medical Center, Omaha. 4. Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. University of the Witwatersrand, Johannesburg, South Africa. 6. Research Institute for Health Sciences and Faculty of Medicine, Chiang Mai University, Thailand. 7. University of the Witwatersrand and Baragwanath Hospital, Soweto, South Africa. 8. Center for Clinical Global Health Education, Johns Hopkins University School of Medicine, Baltimore, Maryland. 9. Antiviral Research Center, University of California, San Diego. 10. Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. 11. College of Pharmacy, University of Nebraska Medical Center, Omaha Infectious Diseases, Internal Medicine, University of Nebraska Medical Center, Omaha.
Abstract
BACKGROUND: Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency virus (HIV)-infected individuals receiving a 4-week regimen to prevent tuberculosis. METHODS: Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy. Efavirenz apparent oral clearance was estimated and the geometric mean ratio (GMR) of values before and during rifapentine and isoniazid was calculated. HIV type 1 (HIV-1) RNA was measured at baseline and week 8. RESULTS:Eighty-seven participants were evaluable: 54% were female, and the median age was 35 years (interquartile range [IQR], 29-44 years). Numbers of participants with efavirenz concentrations ≥1 mg/L were 85 (98%) at week 0; 81 (93%) at week 2; 78 (90%) at week 4; and 75 (86%) at weeks 2 and 4. Median efavirenz apparent oral clearance was 9.3 L/hour (IQR, 6.42-13.22 L/hour) at baseline and 9.8 L/hour (IQR, 7.04-15.59 L/hour) during rifapentine/isoniazid treatment (GMR, 1.04 [90% confidence interval, .97-1.13]). Seventy-nine of 85 (93%) participants had undetectable HIV-1 RNA (<40 copies/mL) at entry; 71 of 75 (95%) participants had undetectable HIV-1 RNA at week 8. Two participants with undetectable HIV-1 RNA at study entry were detectable (43 and 47 copies/mL) at week 8. CONCLUSIONS: The proportion of participants with midinterval efavirenz concentrations ≥1 mg/L did not cross below the prespecified threshold of >80%, and virologic suppression was maintained. Four weeks of daily rifapentine plus isoniazid can be coadministered with efavirenz without clinically meaningful reductions in efavirenz mid-dosing concentrations or virologic suppression. CLINICAL TRIALS REGISTRATION: NCT 01404312.
RCT Entities:
BACKGROUND: Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency virus (HIV)-infected individuals receiving a 4-week regimen to prevent tuberculosis. METHODS:Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy. Efavirenz apparent oral clearance was estimated and the geometric mean ratio (GMR) of values before and during rifapentine and isoniazid was calculated. HIV type 1 (HIV-1) RNA was measured at baseline and week 8. RESULTS: Eighty-seven participants were evaluable: 54% were female, and the median age was 35 years (interquartile range [IQR], 29-44 years). Numbers of participants with efavirenz concentrations ≥1 mg/L were 85 (98%) at week 0; 81 (93%) at week 2; 78 (90%) at week 4; and 75 (86%) at weeks 2 and 4. Median efavirenz apparent oral clearance was 9.3 L/hour (IQR, 6.42-13.22 L/hour) at baseline and 9.8 L/hour (IQR, 7.04-15.59 L/hour) during rifapentine/isoniazid treatment (GMR, 1.04 [90% confidence interval, .97-1.13]). Seventy-nine of 85 (93%) participants had undetectable HIV-1 RNA (<40 copies/mL) at entry; 71 of 75 (95%) participants had undetectable HIV-1 RNA at week 8. Two participants with undetectable HIV-1 RNA at study entry were detectable (43 and 47 copies/mL) at week 8. CONCLUSIONS: The proportion of participants with midinterval efavirenz concentrations ≥1 mg/L did not cross below the prespecified threshold of >80%, and virologic suppression was maintained. Four weeks of daily rifapentine plus isoniazid can be coadministered with efavirenz without clinically meaningful reductions in efavirenz mid-dosing concentrations or virologic suppression. CLINICAL TRIALS REGISTRATION: NCT 01404312.
Authors: Mauro Schechter; Roberto Zajdenverg; Gisely Falco; Grace Link Barnes; José Cláudio Faulhaber; Jacqueline S Coberly; Richard D Moore; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2006-02-10 Impact factor: 21.405
Authors: C V Fletcher; R C Brundage; T Fenton; C G Alvero; C Powell; L M Mofenson; S A Spector Journal: Clin Pharmacol Ther Date: 2007-07-04 Impact factor: 6.875
Authors: Timothy R Sterling; Nigel A Scott; Jose M Miro; Guilherme Calvet; Alberto La Rosa; Rosa Infante; Michael P Chen; Debra A Benator; Fred Gordin; Constance A Benson; Richard E Chaisson; M Elsa Villarino Journal: AIDS Date: 2016-06-19 Impact factor: 4.177
Authors: Molebogeng X Rangaka; Solange C Cavalcante; Ben J Marais; Sok Thim; Neil A Martinson; Soumya Swaminathan; Richard E Chaisson Journal: Lancet Date: 2015-10-26 Impact factor: 79.321
Authors: Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson Journal: N Engl J Med Date: 2019-03-14 Impact factor: 91.245
Authors: Michelle M Pham; Anthony T Podany; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Wadzanai Samaneka; Ayotunde Omoz-Oarhe; Deborah Langat; Constance A Benson; Richard E Chaisson; Susan Swindells; Courtney V Fletcher Journal: Antimicrob Agents Chemother Date: 2022-08-09 Impact factor: 5.938
Authors: Kristina M Brooks; Jomy M George; Alice K Pau; Adam Rupert; Carolina Mehaffy; Prithwiraj De; Karen M Dobos; Anela Kellogg; Mary McLaughlin; Maryellen McManus; Raul M Alfaro; Colleen Hadigan; Joseph A Kovacs; Parag Kumar Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh Journal: Int J Tuberc Lung Dis Date: 2018-06-01 Impact factor: 2.373
Authors: Abriana Tasillo; Joshua A Salomon; Thomas A Trikalinos; C Robert Horsburgh; Suzanne M Marks; Benjamin P Linas Journal: JAMA Intern Med Date: 2017-12-01 Impact factor: 44.409
Authors: A T Podany; J Leon-Cruz; J Hakim; K Supparatpinyo; A Omoz-Oarhe; D Langat; N Mwelase; C Kanyama; A Gupta; C A Benson; R E Chaisson; S Swindells; C V Fletcher Journal: J Antimicrob Chemother Date: 2021-02-11 Impact factor: 5.758